Romedepsin (RM), A Hdaci, Significantly Increases The Expression Of NKG2D Ligands, MIC A/B, In Leukemia/Lymphoma Cells (LL), In Part Through The Glycogen Synthase Kinase-3 (GSK-3) Pathway, Resulting In Enhanced NK Cytotoxicity: Translational Approach For Adoptive NK Cell Immunotherapy